Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4911.29% is 10% above its 5-year average of -5476.81%, near the high end of its 5-year range (-69183.87%–-363.59%).
18.88% above its 12-month average of -6054.68%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -6319.95%.
EBITDA MARGIN
-4911.29%
EBITDA MARGIN AVG TTM
-6054.68%
EBITDA MARGIN AVG 3Y
-4966.71%
EBITDA MARGIN AVG 5Y
-5476.81%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.88%
CURRENT VS 3Y AVG
+1.12%
CURRENT VS 5Y AVG
+10.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Humacyte, Inc.
Market Cap
$84.00M
EBITDA Margin
-4911.29%
TTM Avg
-6054.68%
3Y Avg
-4966.71%
5Y Avg
-5476.81%
Market Cap
$83.96M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.70M
EBITDA Margin
31.45%
TTM Avg
-14.67%
3Y Avg
-906.21%
5Y Avg
-1050.55%
Market Cap
$84.75M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.86M
EBITDA Margin
-8103.88%
TTM Avg
-7583.93%
3Y Avg
-8667.05%
5Y Avg
-7944.60%
Market Cap
$88.21M
EBITDA Margin
15.84%
TTM Avg
9.89%
3Y Avg
0.86%
5Y Avg
4.00%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $84.00M | -4911.29% | -6054.68% | -4966.71% | -5476.81% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | 31.45% | -14.67% | -906.21% | -1050.55% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 23.63% | 23.21% | 8.97% | 9.09% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -8103.88% | -7583.93% | -8667.05% | -7944.60% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 15.84% | 9.89% | 0.86% | 4.00% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -128297.25% | -89238.38% | -49477.43% | -36037.89% |
Gross Margin
-736.5%
EBITDA Margin
-4911.3%
Operating Margin
-5271.7%
Net Margin
-4560.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -6319.95% |
| 2026-03-31 | -5483.84% |
| 2025-12-31 | -6220.13% |
| 2025-09-30 | -2991.37% |
| 2025-06-30 | -9258.14% |
| 2025-03-31 | -4129.98% |
| 2024-12-31 | -363.59% |
| 2022-09-30 | -69183.87% |
| 2022-06-30 | -1269.02% |
| 2022-03-31 | -8460.09% |
| 2021-12-31 | -11062.71% |
| 2021-09-30 | -7669.71% |
| 2021-06-30 | -2493.19% |
| 2021-03-31 | -11750.97% |
| 2020-12-31 | -10963.71% |
| 2020-09-30 | -1655.47% |
| 2020-06-30 | -6191.41% |
| 2020-03-31 | -5985.88% |
